Skip to main content

Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder

Newswire.ca - Thu Dec 12, 2024

Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting

LOUISVILLE, Colo., Dec. 12, 2024  /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") the market leader in cannabidiol (CBD) hemp extract wellness products, is pleased to share an update on the progress of DeFloria LLC's ("DeFloria") botanical pharmaceutical development, an entity established by AJNA BioSciences and Charlotte's Web. Promising findings from DeFloria's Phase 1 clinical trial results for AJA001 were presented by Dr. Marcel Bonn-Miller at the American College of Neuropsychopharmacology Annual Meeting on December 11, 2024. AJA001 is being developed for the treatment of symptoms of autism spectrum disorder (ASD).

Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.